July 26, 2016
Bristol-Myers Squibb Company has announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC).
Opdivo is a human antibody that is used for alleviating immune suppression. JNJ-64041757 is used for inducing the local recruitment and activation of innate and adaptive effector cells and expansion of mesothelin-specific T cells. The Phase 2 clinical trial will evaluate the clinical activity and tolerability of the combination of these agents in NSCLC patients.
Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb, said: “We are excited to collaborate with Janssen as we explore how the emerging science of antigen-presentation therapeutics, in combination with Opdivo, can potentially provide a new treatment approach for patients with lung cancer.”